These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 33905096)

  • 1. Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.
    Buonacera A; Stancanelli B; Malatino L
    High Blood Press Cardiovasc Prev; 2021 Jul; 28(4):331-332. PubMed ID: 33905096
    [No Abstract]   [Full Text] [Related]  

  • 2. Cause and duration of heart failure may impact on the response to sacubitril/valsartan in patients with heart failure and reduced ejection fraction.
    Mandal AKJ; Missouris CG
    J Cardiovasc Med (Hagerstown); 2021 Mar; 22(3):233-234. PubMed ID: 32925393
    [No Abstract]   [Full Text] [Related]  

  • 3. Adoption of Sacubitril/Valsartan Among Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The Get With The Guidelines-Heart Failure Registry.
    Pierce JB; Li Z; Greiner MA; Lippmann SJ; Hardy NC; Shen X; Stampehl M; Mentz RJ; Allen LA; Peterson PN; Fonarow GC; O'Brien EC; Greene SJ
    Circ Heart Fail; 2023 Jan; 16(1):e010176. PubMed ID: 36314141
    [No Abstract]   [Full Text] [Related]  

  • 4. Association Between Sacubitril/Valsartan Initiation and Mitral Regurgitation Severity in Heart Failure With Reduced Ejection Fraction: The PROVE-HF Study.
    Januzzi JL; Omar AMS; Liu Y; Murphy S; Butler J; Felker GM; Piña IL; Ward J; Solomon S; Contreras J
    Circulation; 2022 Nov; 146(21):1638-1640. PubMed ID: 36183276
    [No Abstract]   [Full Text] [Related]  

  • 5. The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.
    Martens P; Beliën H; Dupont M; Vandervoort P; Mullens W
    Cardiovasc Ther; 2018 Aug; 36(4):e12435. PubMed ID: 29771478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Letter by Wu and Zhao Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
    Wu K; Zhao S
    Circulation; 2020 Jul; 142(1):e3-e4. PubMed ID: 32628545
    [No Abstract]   [Full Text] [Related]  

  • 7. Strength in synergy: Cardiometabolic effects of sacubitril/valsartan in heart failure and diabetes.
    Seferović PM; Polovina M; Seferović J; Rosano G
    Int J Cardiol; 2023 Jan; 371():293-294. PubMed ID: 36115444
    [No Abstract]   [Full Text] [Related]  

  • 8. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response by Jackson et al to Letter Regarding Article, "Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF".
    Jackson AM; Jhund PS; Solomon SD; McMurray JJV
    Circulation; 2020 Jul; 142(1):e5-e6. PubMed ID: 32628550
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?
    Gallo G; Rubattu S; Volpe M
    High Blood Press Cardiovasc Prev; 2021 Nov; 28(6):541-545. PubMed ID: 34750764
    [No Abstract]   [Full Text] [Related]  

  • 11. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
    Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
    N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of patients hospitalized for acute heart failure and discharged from an emergency medicine ward with sacubitril-valsartan: differences with patients in the PIONEER-HF and TRANSITION studies.
    Gabrielli M; Romani GR; Franceschi F
    J Cardiovasc Med (Hagerstown); 2023 Mar; 24(3):203-205. PubMed ID: 36724400
    [No Abstract]   [Full Text] [Related]  

  • 13. Real-world treatment switching to sacubitril/valsartan in patients with heart failure with reduced ejection fraction: A cohort study.
    Ganesananthan S; Shah N; Shah P; Elsayed H; Phillips J; Parkes A; Morgan A; Yousef Z
    Open Heart; 2020 Oct; 7(2):. PubMed ID: 33020255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and Healthcare Utilization Among Veterans Treated for Heart Failure With Reduced Ejection Fraction Who Switched to Sacubitril/Valsartan.
    Mohanty AF; Levitan EB; Dodson JA; Vardeny O; King JB; LaFleur J; He T; Patterson OV; Alba PR; Russo PA; Choi ME; Bress AP
    Circ Heart Fail; 2019 Nov; 12(11):e005691. PubMed ID: 31718321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction.
    Mapelli M; Salvioni E; de Martino F; Mattavelli I; Bonomi A; Sassi V; Gugliandolo P; Vignati C; Magini A; Rovai S; Paolillo S; Agostoni P
    J Cardiovasc Med (Hagerstown); 2020 Nov; 21(11):882-888. PubMed ID: 32740412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sacubitril/Valsartan and Rhabdomyolysis: Reanalysis of a Potential Safety Signal.
    Woods RH
    Am J Cardiol; 2022 Jun; 173():145-146. PubMed ID: 35430084
    [No Abstract]   [Full Text] [Related]  

  • 17. Renal effects of Sacubitril/Valsartan in heart failure with reduced ejection fraction: a real life 1-year follow-up study.
    Spannella F; Marini M; Giulietti F; Rosettani G; Francioni M; Perna GP; Sarzani R
    Intern Emerg Med; 2019 Nov; 14(8):1287-1297. PubMed ID: 31147823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. "Real World" Eligibility for Sacubitril/Valsartan in Unselected Heart Failure Patients: Data from the Swedish Heart Failure Registry.
    Simpson J; Benson L; Jhund PS; Dahlström U; McMurray JJV; Lund LH
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):315-322. PubMed ID: 30903545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Sacubitril-valsartan should also be the first choice to be evaluated in the elderly patient with heart failure with reduced ejection fraction].
    Camafort M; Formiga F
    Rev Esp Geriatr Gerontol; 2021; 56(2):67-68. PubMed ID: 33526274
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.